AVEO Pharmaceuticals presented preclinical data this month at the American Association for Cancer Research (AACR) annual meeting demonstrating that its Notch1-specific monoclonal antibody is a highly potent inhibitor of Notch1 function in both in vitro and in vivo models. Effective blockade of Notch signaling has been demonstrated to effectively inhibit tumor angiogenesis.
According to Tuan Ha-Ngoc, AVEO President and CEO, “the Notch pathway plays a critical role in the maintenance of tumors. The activity of our Notch1 targeted monoclonal antibody seen in preclinical data to date highlights the potential utility of this therapy." Recent data have also suggested an important role for Notch signaling in cancer stem cell maintenance.
- here's the release from AVEO
Aveo proves investors still lack appetite for biotech IPOs
Aveo Pharma delays IPO, at least briefly
AVEO Pharmaceuticals - Top 20 VC deals of 2007